Absolute Risk Reduction (ARR): the absolute difference in the percentage of patients who did not develop grade 4 neutropenia in the test group versus the control group.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast ...

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

Side effects after Botox are usually temporary and involve swelling or bruising at the injection site. Learn what could be ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.